DXCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Dexcom Inc (DXCM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive market sentiment, and favorable analyst ratings, making it a solid choice for long-term investment.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is in the neutral zone, suggesting no immediate overbought or oversold conditions. The stock is trading near its resistance level (R1: 74.145) but remains below R2 (76.89), showing potential for further upside. Moving averages are converging, signaling stability in price trends.
Strong Q4 financial performance with revenue up 13.12% YoY, net income up 76.20% YoY, and EPS up 81.08% YoY.
Analysts have raised price targets, with most maintaining Outperform or Buy ratings.
Increasing adoption of Dexcom's CGM devices, supported by the rise of GLP-1 drugs, presents a significant market opportunity.
Favorable sentiment in the healthcare sector for 2026.
Investigation by Halper Sadeh LLC into potential fiduciary breaches, which could lead to corporate governance reforms.
Barclays maintains an Underweight rating with a lower price target of $72, reflecting some skepticism.
Dexcom reported strong financial results for Q4 2025. Revenue increased by 13.12% YoY to $1.26 billion, net income surged by 76.20% YoY to $267.3 million, and EPS grew by 81.08% YoY to 0.67. Gross margin improved to 70.3%, up 10.36% YoY, showcasing robust profitability and operational efficiency.
Analysts are generally positive on Dexcom, with multiple firms raising price targets and maintaining Outperform or Buy ratings. The price targets range from $72 (Barclays) to $95 (Canaccord), with the majority clustered in the $86-$90 range. Analysts highlight the company's strong market position, product innovation, and growth potential as key drivers.
